Clinical experience with 5-aza-2′-deoxycitidine in myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) in both untreated and relapsed/refractory patients.
| . | Randomized 3-day (%)20 . | 5-day schedule (%)14 . | Combination with valproic acid (%)42 . | Combination with valproic acid in untreated patients (%)42 . |
|---|---|---|---|---|
| * Includes patients with AML and relapsed and refractory disease. | ||||
| Abbreviations: N, number; CR, complete remission; PR, partial remission; HI, hematologic improvement; OR, overall response. | ||||
| Phase | 3 | 2 | 1/2 | 1/2 |
| N | 89 | 95 | 53 | 10 |
| CR, no. (%) | 8 (9) | 32 (34) | 10 (19) | 4 (40) |
| PR, no. (%) | 7 (8) | 1 (1) | 2 (4) | 1 (10) |
| HI, no. (%) | 12 (13) | 13 (13) | NA | 0 |
| OR, no. (%) | 27 (30) | 46 (48) | 12 (23) | 5 (50) |
| . | Randomized 3-day (%)20 . | 5-day schedule (%)14 . | Combination with valproic acid (%)42 . | Combination with valproic acid in untreated patients (%)42 . |
|---|---|---|---|---|
| * Includes patients with AML and relapsed and refractory disease. | ||||
| Abbreviations: N, number; CR, complete remission; PR, partial remission; HI, hematologic improvement; OR, overall response. | ||||
| Phase | 3 | 2 | 1/2 | 1/2 |
| N | 89 | 95 | 53 | 10 |
| CR, no. (%) | 8 (9) | 32 (34) | 10 (19) | 4 (40) |
| PR, no. (%) | 7 (8) | 1 (1) | 2 (4) | 1 (10) |
| HI, no. (%) | 12 (13) | 13 (13) | NA | 0 |
| OR, no. (%) | 27 (30) | 46 (48) | 12 (23) | 5 (50) |